Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wockhardt launches generic midazolam injections in the US

This article was originally published in Scrip

Executive Summary

Wockhardt has launched preservative-free midazolam injections 1mg/ml and 5mg/ml in the US. The product is a generic version of Roche's Versed for acute insomnia and anxiety and represents Wockhardt's fourth injection ANDA approval in the past two months and the twelfth sterile product to be approved in the US. Wockhardt now has FDA approval for both preservative-free injections containing midazolam, and midazolam injections containing preservatives. The injections are manufactured at Wockhardt's US FDA-certified formulation plant in Waluj. The US market for midazolam injections is estimated at $56 million.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC032050

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel